Commentary on the Prognostic Impact of Pre- and Post-Procedural Renal Dysfunction on Late All-Cause Mortality Outcome Following Transcatheter Edge-to-Edge Repair of the Mitral Valve
The COAPT (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional Mitral Regurgitation) trial demonstrated the powerful impact transcatheter edge-to-edge mitral valve repair (TEER) has and continues to have on our heart failure patients with symptomatic functional moderate-severe and severe mitral regurgitation. Careful patient selection for TEER with the optimization of heart failure medications using goal-directed medical therapy has proven to have a significant role, demonstrating improved survival and reducing heart failure hospitalizations .